chlorambucil,venetoclax,obinutuzumab
abbvie,roche
['cll14', 'cll']
update of #cll14 #icml2023, 60% of patients not requiring treatment 6 years after 12 months fixed duration ven-o, my takeaway was the os difference based on mrd positivity 
Consultant Haematologist UCLH & UCL. Interested in Lymphoma, CAR-T, CLL, Histiocytic Disorders & HLH